Effectiveness and Safety of Anti-interleukin-17 Therapies in Elderly Patients with Psoriasis

Anti-interleukin-17 agents have recently been developed for the treatment of psoriasis. This study evaluated the tolerance and effectiveness of anti-interleukin-17 agents for psoriasis in elderly patients in daily practice. A multicentre, retrospective study was performed, involving psoriatic patients aged ≥65 years who had received an anti-interleukin-17 agent, including secukinumab, ixekizumab or brodalumab. A total of 114 patients were included: 72 received secukinumab, 35 ixekizumab, and 7 brodalumab. Treatment was stopped in 32 patients (28.9%), because of relapses in 14 patients (41.2%), primary failures in 11 patients (32.4%), or adverse events in 7 patients (20.6%). The 3 most frequently reported adverse events were injection site reactions (n = 4), oral candidiasis (n = 3), and influenza-like illness (n = 3). Regarding effectiveness, 80 patients (70%) reached a Physician Global Assessment score of 0/1, 6 months after treatment initiation. In conclusion, anti-interleukin-17 therapy appears to be an effective and safe therapeutic option for psoriasis treatment in patients aged ≥ 65 years.

Citing Articles

Efficacy and Safety of Secukinumab in Elderly Patients with Moderate to Severe Plaque-Type Psoriasis: Post-Hoc Analysis of the SUPREME Study.

Talamonti M, Russo F, Malara G, Hansel K, Papini M, Cattaneo A Clin Cosmet Investig Dermatol. 2023; 16:847-852.

PMID: 37033782 PMC: 10075320. DOI: 10.2147/CCID.S400520.

Therapy of PsO in Special Subsets of Patients.

Di Cesare A, Ricceri F, Rosi E, Fastame M, Prignano F Biomedicines. 2022; 10(11).

PMID: 36359399 PMC: 9687729. DOI: 10.3390/biomedicines10112879.

Drug Survival, Safety, and Effectiveness of Biologics in Older Patients with Psoriasis: A Comparison with Younger Patients-A BioCAPTURE Registry Study.

Ter Haar E, Thomas S, van den Reek J, Otero M, Njoo M, Ossenkoppele P Drugs Aging. 2022; 39(9):715-727.

PMID: 35859228 PMC: 9300332. DOI: 10.1007/s40266-022-00961-y.

Oral Infection in Psoriatic Patients Treated with IL17A Inhibitors: Report of 3 Cases and a Comprehensive Review of the Literature.

Pettas E, Savva V, Theofilou V, Georgaki M, Nikitakis N Diagnostics (Basel). 2022; 12(1).

PMID: 35054170 PMC: 8774305. DOI: 10.3390/diagnostics12010003.

Use of Biological Treatments in Elderly Patients with Skin Psoriasis in the Real World.

Osuna C, Garcia S, Martin J, Jimenez V, Lopez F, Santos-Juanes J Life (Basel). 2021; 11(12).

PMID: 34947880 PMC: 8705752. DOI: 10.3390/life11121348.

References

Griffiths C, Reich K, Lebwohl M, van de Kerkhof P, Paul C, Menter A . Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. Lancet. 2015; 386(9993):541-51. DOI: 10.1016/S0140-6736(15)60125-8. View

Sandhu V, Ighani A, Fleming P, Lynde C . Biologic Treatment in Elderly Patients With Psoriasis: A Systematic Review. J Cutan Med Surg. 2020; 24(2):174-186. DOI: 10.1177/1203475419897578. View

Papp K, Langley R, Sigurgeirsson B, Abe M, Baker D, Konno P . Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study. Br J Dermatol. 2012; 168(2):412-21. DOI: 10.1111/bjd.12110. View

Korber A, Papavassilis C, Bhosekar V, Reinhardt M . Efficacy and Safety of Secukinumab in Elderly Subjects with Moderate to Severe Plaque Psoriasis: A Pooled Analysis of Phase III Studies. Drugs Aging. 2018; 35(2):135-144. PMC: 5847154. DOI: 10.1007/s40266-018-0520-z. View

Kamel J, Yamauchi P . Managing Mild-to-Moderate Psoriasis in Elderly Patients: Role of Topical Treatments. Drugs Aging. 2017; 34(8):583-588. DOI: 10.1007/s40266-017-0480-8. View

Papp K, Reich K, Paul C, Blauvelt A, Baran W, Bolduc C . A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis. Br J Dermatol. 2016; 175(2):273-86. DOI: 10.1111/bjd.14493. View

Balato N, Patruno C, Napolitano M, Patri A, Ayala F, Scarpa R . Managing moderate-to-severe psoriasis in the elderly. Drugs Aging. 2014; 31(4):233-8. DOI: 10.1007/s40266-014-0156-6. View

Blauvelt A, Reich K, Tsai T, Tyring S, Vanaclocha F, Kingo K . Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR study. J Am Acad Dermatol. 2016; 76(1):60-69.e9. DOI: 10.1016/j.jaad.2016.08.008. View

Stuart P, Malick F, Nair R, Henseler T, Lim H, Jenisch S . Analysis of phenotypic variation in psoriasis as a function of age at onset and family history. Arch Dermatol Res. 2002; 294(5):207-13. DOI: 10.1007/s00403-002-0321-3. View

10.

Hueber W, Patel D, Dryja T, Wright A, Koroleva I, Bruin G . Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci Transl Med. 2010; 2(52):52ra72. DOI: 10.1126/scitranslmed.3001107. View

11.

Kwon H, Kwon I, Youn J . Clinical study of psoriasis occurring over the age of 60 years: is elderly-onset psoriasis a distinct subtype?. Int J Dermatol. 2011; 51(1):53-8. DOI: 10.1111/j.1365-4632.2011.04979.x. View

12.

Gordon K, Blauvelt A, Papp K, Langley R, Luger T, Ohtsuki M . Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis. N Engl J Med. 2016; 375(4):345-56. DOI: 10.1056/NEJMoa1512711. View

13.

Phan C, Sigal M, Esteve E, Reguiai Z, Barthelemy H, Beneton N . Psoriasis in the elderly: epidemiological and clinical aspects, and evaluation of patients with very late onset psoriasis. J Eur Acad Dermatol Venereol. 2014; 30(1):78-82. DOI: 10.1111/jdv.12850. View

14.

Henseler T, Christophers E . Psoriasis of early and late onset: characterization of two types of psoriasis vulgaris. J Am Acad Dermatol. 1985; 13(3):450-6. DOI: 10.1016/s0190-9622(85)70188-0. View

15.

Lebwohl M, Strober B, Menter A, Gordon K, Weglowska J, Puig L . Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis. N Engl J Med. 2015; 373(14):1318-28. DOI: 10.1056/NEJMoa1503824. View

16.

Mease P, McInnes I, Kirkham B, Kavanaugh A, Rahman P, van der Heijde D . Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis. N Engl J Med. 2015; 373(14):1329-39. DOI: 10.1056/NEJMoa1412679. View

17.

Di Lernia V, Goldust M . An overview of the efficacy and safety of systemic treatments for psoriasis in the elderly. Expert Opin Biol Ther. 2018; 18(8):897-903. DOI: 10.1080/14712598.2018.1504016. View

18.

Piaserico S, Conti A, Lo Console F, De Simone C, Prestinari F, Mazzotta A . Efficacy and safety of systemic treatments for psoriasis in elderly patients. Acta Derm Venereol. 2013; 94(3):293-7. DOI: 10.2340/00015555-1719. View

19.

Langley R, Elewski B, Lebwohl M, Reich K, Griffiths C, Papp K . Secukinumab in plaque psoriasis--results of two phase 3 trials. N Engl J Med. 2014; 371(4):326-38. DOI: 10.1056/NEJMoa1314258. View